Measuring endogenous changes in serotonergic neurotransmission in humans: A [11C] CUMI-101 PET challenge study

Molecular Psychiatry

Volumn 17, Issue 12, 2012, Pages 1254-1260

  Selvaraj, S ^a,b   Turkheimer, F ^c   Rosso, L ^c   Faulkner, P ^d   Mouchlianitis, E ^a   Roiser, J P ^d   McGuire, P ^b   Cowen, P J ^e   Howes, O ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5 HT1A receptor; antidepressants; citalopram; neuroimaging; positron emission tomography; serotonin or 5 HT

Indexed keywords

CITALOPRAM; CUMI 101 C 11; RADIOLIGAND; SEROTONIN; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DORSAL RAPHE NUCLEUS; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NEUROIMAGING; NEUROTRANSMISSION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SEROTONERGIC NEUROTRANSMISSION; SEROTONINERGIC SYSTEM;

ADULT; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RAPHE NUCLEI; SEROTONERGIC NEURONS; SEROTONIN; SYNAPTIC TRANSMISSION; TRIAZINES;

EID: 84870055977     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.78     Document Type: Article

References (52)

1. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240.
2. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574.
3. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33: 1109-1132.
4. Brooks DJ. PET studies on the function of dopamine in health and Parkinson's disease. Ann N Y Acad Sci 2003; 991: 22-35.
5. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 2010; 30: 1682-1706.
6. Sibon I, Benkelfat C, Gravel P, Aznavour N, Costes N, Mzengeza S et al. Decreased [18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: a positron-emission tomography study in healthy volunteers. Biol Psychiatry 2008; 63: 1135-1140.
7. Malagie I, Trillat AC, Jacquot C, Gardier AM. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol 1995; 286: 213-217.
8. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995; 115: 1064-1070.
9. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-383.
10. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229: 101-103.
11. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-1152.
12. Gartside SE, Clifford EM, Cowen PJ, Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol 1999; 127: 145-152.
13. Romero L, Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem 1997; 68: 2593-2603.
14. Hjorth S, Auerbach SB. 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 1996; 73: 281-283.
15. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992; 584: 322-324.
16. de Montigny C, Blier P, Chaput Y. Electrophysiologically-identified serotonin receptors in the rat CNS. Effect of antidepressant treatment. Neuropharmacology 1984; 23: 1511-1520.
17. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 342-348.
18. Adell A, Artigas F. Effects of clomipramine on extracellular serotonin in the rat frontal cortex. Adv Exp Med Biol 1991; 294: 451-454.
19. Giovacchini G, Lang L, Ma Y, Herscovitch P, Eckelman WC, Carson RE. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. NeuroImage 2005; 28: 238-248.
20. Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology 1995; 34: 89-96.
21. Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H et al. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2, 4-triazine-3, 5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imag 2007; 34: 1050-1060.
22. Milak MS, Severance AJ, Prabhakaran J, Kumar JS, Majo VJ, Ogden RT et al. In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer. J Cereb Blood Flow Metab 2011; 31: 243-249.
23. Milak MS, DeLorenzo C, Zanderigo F, Prabhakaran J, Kumar JS, Majo VJ et al. In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med 2010; 51: 1892-1900.
24. Prabhakaran J, Parsey RV, Majo VJ, Hsiung SC, Milak MS, Tamir H et al. Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3, 5-dione: a novel agonist 5-HT1A receptor PET ligand. Bioorg Med Chem Lett 2006; 16: 2101-2104.
25. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for the DSM-IV (SCID-I/P). American Psychiatric Press: Washington, 2004.
26. Hinz R, Selvaraj S, Murthy NV, Bhagwagar Z, Taylor M, Cowen PJ et al. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J Cereb Blood Flow Metab 2008; 28: 1478-1490.
27. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology (Berl) 2001; 155: 323-326.
28. Kemp BJ, Kim C, Williams JJ, Ganin A, Lowe VJ. NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. J Nucl Med 2006; 47: 1960-1967.
29. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 1999; 19: 1189-1208.
30. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25-35.
31. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L et al. Threedimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19: 224-247.
32. Selvaraj S, Murthy NV, Bhagwagar Z, Bose SK, Hinz R, Grasby PM et al. Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) 2011; 213: 555-562.
33. Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, Majo VJ et al. Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med 2008; 49: 587-596.
34. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-747.
35. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK et al. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995; 15: 152-165.
36. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 2010; 30: 46-50.
37. Turkheimer FE, Selvaraj S, Hinz R, Murthy V, Bhagwagar Z, Grasby P et al. Quantification of ligand PET studies using a reference region with a displaceable fraction: application to occupancy studies with [(11)C]-DASB as an example. J Cereb Blood Flow Metab 2012; 32: 70-80.
38. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
39. Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. NeuroImage 1998; 8: 426-440.
40. Fuller RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163-167.
41. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005; 32: 123-128.
42. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004; 22: 246-260.
43. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331-343.
44. Blier P, Serrano A, Scatton B. Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse 1990; 5: 120-133.
45. Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009; 34: 2275-2284.
46. Palner M, Underwood MD, Kumar DJ, Arango V, Knudsen GM, John Mann J et al. Ex vivo evaluation of the serotonin 1A receptor partial agonist [(3)H]CUMI-101 in awake rats. Synapse 2011; 65: 715-723.
47. Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H et al. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2, 4-triazine-3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imag 2007; 34: 1050-1060.
48. Liow J-S, Lu S, Zoghbi S, Shrestha S, Gladding R, Morse C et al. Selectivity in rodents and monkeys of 11C-CUMI-101, an agonist radioligand for serotonin 5-HT1A receptors. J Nucl Med Meet Abstr 2010; 51: 164-16.
49. Hendry N, Christie I, Rabiner EA, Laruelle M, Watson J. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. Nucl Med Biol 2011; 38: 273-277.
50. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF et al. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage 2006; 30: 341-348.
51. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338-343.
52. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006; 311: 861-863.